Envoy Medical, Inc.

Envoy Medical, Inc. develops and commercializes implantable hearing devices, with current revenue coming primarily from the Esteem FI-AMEI fully implanted active middle ear implant and related replacement components. The company is also advancing its Acclaim CI cochlear implant program, which is still in clinical development and targeted for future FDA approval and commercialization.

−9 115,4 %

−262,7 %

−9 857,3 %

+7,1 %

0.54

0.41

— Envoy Medical, Inc.
%
Commercial hearing implants90% Sales of the Esteem FI-AMEI implant system and related replacement components used in implanted patients.
Replacement and consumables10% Battery/sound processor replacements and other recurring post-implant components for existing patients.
Clinical development programs0% R&D work for the Acclaim CI cochlear implant and continued support for the Esteem platform.

Envoy Medical sells to patients and the clinical providers who implant and manage its hearing devices, with...

  • Implant patientsprimary

    Patients who receive the Esteem FI-AMEI device and later buy replacement components or services.

  • Surgical providersprimary

    ENT surgeons, hospitals, and clinical centers that implant and support the devices.

  • Payers and reimbursement stakeholdersprimary

    Insurers and coverage authorities that determine whether patients can access the devices economically.

  • Future cochlear implant marketemerging

    Potential Acclaim CI customers if the product receives FDA approval and reaches commercialization.

The company is headquartered in the United States and its current commercial activity is centered on the U.S. market...

  • •Headquartered in the United States
  • •Commercial activity is currently centered in the U.S.
  • •FDA clinical development and approval process is U.S.-based
  • •Reimbursement strategy is focused on U.S. coverage decisions
  • •No country-level revenue disclosure was provided in the excerpts

Envoy Medical is focused on extending the life of its current implant franchise while advancing Acclaim CI through...

01
Complete Acclaim CI clinical developmentmedium-term

The product is the main future growth driver and requires successful trial execution before PMA filing.

02
Secure FDA approval and commercialization readinessmedium-term

Regulatory clearance is required before Acclaim CI can generate meaningful revenue.

03
Improve reimbursement coverageshort-term

Coverage changes could materially expand patient access and implant volumes.

04
Maintain liquidity and fund operationsshort-term

The company is loss-making and depends on external financing to support trials and operations.

Envoy Medical faces substantial execution risk because it is still funding clinical development and has a limited...

high

Regulatory and clinical development delay

Acclaim CI must complete staged trials and PMA review before commercialization, so any delay pushes out revenue and increases cash burn.

Scope
Acclaim CI program
Materiality
high
high

Reimbursement and coverage risk

The company explicitly relies on positive reimbursement changes to expand implant volumes and patient access.

Scope
Esteem FI-AMEI and future Acclaim CI adoption
Materiality
high
high

Liquidity and financing risk

The company has incurred significant operating losses and has funded operations primarily through equity and debt financing.

Scope
Corporate operations and clinical trials
Materiality
high
medium

Commercial concentration risk

Current revenue comes substantially all from a single product family and a very small number of implant events.

Scope
Esteem FI-AMEI implants and replacements
Materiality
high
medium

Inventory and manufacturing risk

The company carries excess/obsolete inventory reserves and write-offs, which can rise if demand remains low or product mix changes.

Scope
Cost of goods sold and gross margin
Materiality
medium
Point-in-time revenue recognition
Can shift revenue between quarters and make trends lumpy
Inventory reserves and write-offs
Affects gross margin and operating loss
Fair value measurements
Can create non-cash gains or losses
Stock-based compensation
Raises operating expenses without immediate cash outflow
Interest expense on related-party and financing arrangements
Can materially change reported bottom-line results

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Enovis CORP

ENOV · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Envista Holdings Corp

NVST · Dental Equipment & Supplies

Enovix Corp

ENVX · Miscellaneous Electrical Machinery, Equipment & Supplies

enVVeno Medical Corp

NVNO · Surgical & Medical Instruments & Apparatus

ENCISION INC

Surgical & Medical Instruments & Apparatus

: 28/04/2026